1. Home
  2. TGTX

TGTX

TG Therapeutics Inc.

Logo TG Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-22-2024 4:00pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.

Founded: N/A Country:
United States
United States
Employees: N/A City: NEW YORK
Market Cap: 2.1B IPO Year: 1995
Target Price: $30.20 AVG Volume (30 days): 3.5M
Analyst Decision: Strong Buy Number of Analysts: 6
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: 0.09 EPS Growth: N/A
52 Week Low/High: $6.46 - $35.67 Next Earning Date: 05-03-2024
Revenue: $233,662,000 Revenue Growth: 8290.02%
Revenue Growth (this year): 15.18% Revenue Growth (next year): 56.41%

Share on Social Networks: